| Qualification Type: | PhD |
|---|---|
| Location: | Swansea |
| Funding for: | UK Students |
| Funding amount: | Full cost of Tuition |
| Hours: | Full Time |
| Placed On: | 17th December 2025 |
|---|---|
| Closes: | 26th February 2026 |
| Reference: | RS916 |
In 2015, the epilepsy medication Spritam became the first and still the only FDA-approved drug manufactured using 3D printing. Since then, research has flourished in developing innovative 3D-printed formulations.
We are seeking a motivated and curious MSc by Research student to join an exciting interdisciplinary project focused on developing an innovative oral drug delivery system. This project aims to create magnetically guided, 3D-printed oral formulations designed for precise localisation and controlled drug release within the gastrointestinal tract.
As part of this research, the student will explore pharmaceutical 3D printing techniques, conduct rheological assessments to ensure material printability, and perform rigorous quality control and drug release studies. The formulations developed have the potential to transform treatment strategies for conditions such as inflammatory bowel disease, gastrointestinal cancers, and severe acid reflux.
Funding Comment
Covers full tuition, as well as additional funding of up to £1,000 for associated research expenses.
Type / Role:
Subject Area(s):
Location(s):